Splash

Media

View our latest materials to follow our progress in tackling respiratory diseases.
Splash
Media

Filters

Email Alerts

Subscribe to our email alerts

17 January 2020Regulatory
Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Jan. 17, 2020 (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to

13 January 2020Company News, Regulatory
Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy

Primary endpoint met at all doses: ensifentrine produced clinically and statistically significant dose-dependent improvements in lung function Clinically relevant secondary endpoints met, including progressive and statistically significant improvements in quality of life Conference call scheduled

10 January 2020Company News
Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy

Data release and conference call on Monday January 13, 2020 LONDON, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, will release results on Monday, January 13, 2020 at 5.00

7 January 2020Company News
Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations

LONDON, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces the appointment of David Moskowitz to the newly created position of Vice President, Capital Markets Strategy

28 November 2019Regulatory
Holding(s) in Company TR-1: Standard form for notification of major holdings

LONDON, Nov. 28, 2019 (GLOBE NEWSWIRE) -- TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i   1a. Identity of the issuer or the underlying issuer of existing shares to

27 November 2019Regulatory
Verona Pharma plc: Grant of Options to PDMR

LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26, 2019, it granted 500,000 options to purchase ordinary shares of £0.05 each (the “Ordinary Shares”) to

Email Alerts

Subscribe to our email alerts

Splash

© Verona Pharma plc 2020. All rights reserved